NewAmsterdam Pharma (NASDAQ:NAMS) Shares Acquired by Barclays PLC

Barclays PLC increased its stake in NewAmsterdam Pharma (NASDAQ:NAMS) by 1,813.4% during the 3rd quarter, Holdings Channel reports. The fund owned 7,596 shares of the company’s stock after purchasing an additional 7,199 shares during the quarter. Barclays PLC’s holdings in NewAmsterdam Pharma were worth $126,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of NAMS. XTX Topco Ltd acquired a new stake in NewAmsterdam Pharma in the third quarter valued at $187,000. Wellington Management Group LLP raised its stake in NewAmsterdam Pharma by 11.0% in the third quarter. Wellington Management Group LLP now owns 92,223 shares of the company’s stock valued at $1,531,000 after buying an additional 9,162 shares in the last quarter. State Street Corp raised its stake in NewAmsterdam Pharma by 168.7% in the third quarter. State Street Corp now owns 37,915 shares of the company’s stock valued at $629,000 after buying an additional 23,805 shares in the last quarter. Quarry LP raised its stake in NewAmsterdam Pharma by 2,469.2% in the third quarter. Quarry LP now owns 6,500 shares of the company’s stock valued at $108,000 after buying an additional 6,247 shares in the last quarter. Finally, Readystate Asset Management LP acquired a new stake in NewAmsterdam Pharma in the third quarter valued at $2,009,000. 89.89% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other NewAmsterdam Pharma news, major shareholder Nap B.V. Forgrowth sold 33,273 shares of NewAmsterdam Pharma stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $25.08, for a total value of $834,486.84. Following the completion of the sale, the insider now directly owns 11,778,760 shares of the company’s stock, valued at approximately $295,411,300.80. The trade was a 0.28 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 446,730 shares of company stock worth $11,438,695 in the last ninety days. Insiders own 19.50% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on NAMS. Scotiabank raised their price objective on NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a “sector outperform” rating in a report on Wednesday, December 11th. Piper Sandler reaffirmed an “overweight” rating and set a $37.00 price objective on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Needham & Company LLC reaffirmed a “buy” rating and set a $36.00 price objective on shares of NewAmsterdam Pharma in a report on Thursday, December 5th. Finally, HC Wainwright began coverage on NewAmsterdam Pharma in a report on Monday, December 30th. They set a “buy” rating and a $48.00 price objective on the stock. Seven analysts have rated the stock with a buy rating, According to MarketBeat, NewAmsterdam Pharma currently has an average rating of “Buy” and a consensus target price of $38.17.

NewAmsterdam Pharma Trading Down 1.9 %

NAMS stock opened at $25.55 on Thursday. The firm has a 50 day moving average of $23.10 and a 200-day moving average of $19.60. NewAmsterdam Pharma has a 12-month low of $12.04 and a 12-month high of $27.29.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.